Focusing on innovative drug therapy for neovascular age-related macular degeneration

Authors: Lu Yingyi,  Zhao Jing,  Dai Hong
DOI: 10.3760/cma.j.cn115989-20231225-00217
Published 2024-05-10
Cite as Chin J Exp Ophthalmol, 2024, 42(5): 401-407.

Abstract                              [Download PDF] [Read Full Text]

Wet age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly, and anti-VEGF is its main treatment method.At present, the treatment of nAMD still faces many shortcomings and challenges, and the development of new therapeutic drugs and delivery methods is the research focus.In recent years, the direction of drug research and development for the treatment of nAMD has shown diversification, including the development of new target/mechanism drugs and new drug delivery methods, optimization of drug dosage and gene therapy, etc., in order to reduce treatment frequency, prolong treatment interval, improve patient compliance, and maintain or improve vision in the long term.Ophthalmologists should have a comprehensive understanding of new drugs and explore strategies appropriate for patients with different subtypes of nAMD to achieve a move toward precision medicine.

Key words:

Age-related macular degeneration; Treatment; Anti-VEGF; Innovative drug

Contributor Information

Lu Yingyi

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Zhao Jing

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Dai Hong

Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

(Read 17 times, 1 visits today)